2096.HKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 17:08):

Stats
本日の出来高	3.42M
平均出来高	5.13M
時価総額	14.09B
EPS	HKD0 ( 2024-03-28 )
次の収益日	( HKD0 ) 2024-06-14
Last Dividend	HKD0.176 ( 2023-06-19 )
Next Dividend	HKD0 ( N/A )
P/E	18.62
ATR14	HKD0.00900 (0.17%)

ボリューム相関

長: 0.07 (neutral)

短: -0.45 (neutral)

Signal:(67.997) Neutral

Simcere Pharmaceutical 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Simcere Pharmaceutical 相関 - 通貨/商品

-0.26
( neutral )

-0.07
( neutral )

0.00
( neutral )

0.28
( neutral )

Simcere Pharmaceutical 財務諸表

Annual	2023
収益:	HKD6.61B
総利益:	HKD4.98B (75.43 %)
EPS:	HKD0.270

FY	2023
収益:	HKD6.61B
総利益:	HKD4.98B (75.43 %)
EPS:	HKD0.270

FY	2023
収益:	HKD0
総利益:	HKD0 (0.00 %)
EPS:	HKD0

FY	2022
収益:	HKD6.32B
総利益:	HKD5.00B (79.08 %)
EPS:	HKD0.400

Financial Reports:

No articles found.

Simcere Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.176 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Simcere Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.58 - good (85.76%) | Divividend Growth Potential Score: 2.73 - Decrease likely (45.45%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.180	2021-06-29
Last Dividend	HKD0.176	2023-06-19
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	HKD0.532	--
Avg. Dividend % Per Year	0.00%	--
Score	2.23	--
Div. Sustainability Score	8.58
Div.Growth Potential Score	2.73
Div. Directional Score	5.65	--

Next Divdend (Est)
(2025-03-31)

HKD0.176 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

2.23

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
1587.HK	Ex Dividend Junior	2023-05-23	Annually	0.00%
0631.HK	Ex Dividend Junior	2023-06-05	Sporadic	0.00%
9919.HK	Ex Dividend Knight	2023-08-24	Semi-Annually	0.00%
2169.HK	Ex Dividend Junior	2023-06-20	Annually	0.00%
1171.HK	Ex Dividend Knight	2023-07-05	Annually	0.00%
0251.HK	Ex Dividend Junior	2023-09-20	Semi-Annually	0.00%
3877.HK	Ex Dividend Junior	2023-06-28	Semi-Annually	0.00%
1739.HK	No Dividend Player	2023-09-05	Sporadic	0.00%
0778.HK	Ex Dividend Junior	2023-08-23	Semi-Annually	0.00%
2331.HK	Ex Dividend Junior	2023-08-23	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.108	1.500	7.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0659	1.200	7.80	9.37	[0 - 0.3]
returnOnEquityTTM	0.0878	1.500	-0.135	-0.203	[0.1 - 1]
payoutRatioTTM	0.587	-1.000	4.13	-4.13	[0 - 1]
currentRatioTTM	2.10	0.800	4.50	3.60	[1 - 3]
quickRatioTTM	1.736	0.800	4.49	3.59	[0.8 - 2.5]
cashRatioTTM	0.747	1.500	6.96	10.00	[0.2 - 2]
debtRatioTTM	0.132	-1.500	7.81	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.0581	2.00	9.98	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.128	2.00	-0.0639	-0.128	[0 - 20]
debtEquityRatioTTM	0.198	-1.500	9.21	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.754	1.000	0.762	0.762	[0.2 - 0.8]
operatingProfitMarginTTM	0.108	1.000	9.85	9.85	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.106	1.000	-0.524	-0.524	[0.2 - 2]
assetTurnoverTTM	0.609	0.800	9.27	7.42	[0.5 - 2]
Total Score				8.58

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.79	1.000	8.30	0	[1 - 100]
returnOnEquityTTM	0.0878	2.50	-0.0869	-0.203	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.128	2.00	-0.0426	-0.128	[0 - 30]
dividendYielPercentageTTM	3.59	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0581	2.00	9.98	10.00	[0 - 30]
payoutRatioTTM	0.587	1.500	4.13	-4.13	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0229	1.000	-1.929	0	[0.1 - 0.5]
Total Score				2.73

Simcere Pharmaceutical

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.